RBC Capital raised the firm’s price target on Incyte (INCY) to $84 from $81 and keeps a Sector Perform rating on the shares after its Q3 earnings beat. The company’s solid commercial performance for Jakafi and Opzelura, along with newly launched products such as Niktimvo, provided additional tailwinds for a top/bottom line beat, reassuring on its base business, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY: